Loading...
•
Mar 31, 2024
Heron Therapeutics Q1 2024 Earnings Report
Heron Therapeutics' financial performance improved with increased revenues, improved gross margins, and reduced net loss per share.
Key Takeaways
Heron Therapeutics reported a net product sales increase to $34.7 million, up from $29.6 million in the same period last year. The company's gross margin significantly improved to 76% from 43% year-over-year, and the net loss per share decreased from $(0.27) to $(0.02).
Net product sales increased to $34.7 million, compared to $29.6 million in the same period of 2023.
Net loss per share improved to $(0.02) from $(0.27) year-over-year.
Gross margin improved significantly to 76%, up from 43% in the prior year.
Partnership with CrossLink Life Sciences, LLC was launched to boost ZYNRELEF promotional activities.
Heron Therapeutics
Heron Therapeutics
Heron Therapeutics Revenue by Segment
Revenue by Segment
CINVANTI Revenue
CapyFin.comSUSTOL Revenue
CapyFin.comZYNRELEF Revenue
CapyFin.comAPONVIE Revenue
CapyFin.com Forward Guidance
Heron Therapeutics reaffirms its full-year 2024 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA.
Positive Outlook
- Product Revenues, Net $138.0 to $158.0 million
- Adjusted Operating Expenses(Excluding Stock-Based Compensation and Depreciation and Amortization) $108.0 to $116.0 million
- Adjusted EBITDA(Excluding Stock-Based Compensation and Depreciation and Amortization) $(22.0) to $3.0 million
Revenue & Expenses
Visualization of income flow from segment revenue to net income